These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38158876)

  • 1. How do we use the National Healthcare Safety Network for Hemovigilance in Massachusetts?
    Iannone A; Cumming M; Osinski A; Brandeburg C; Schultz J; Slider A; Rodrigue B; O'Hearn L; Herman M; McHale E; Rios J; Uhl L; Andrzejewski C; DeMaria A
    Transfusion; 2024 Feb; 64(2):200-209. PubMed ID: 38158876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemovigilance in Massachusetts and the adoption of statewide hospital blood bank reporting using the National Healthcare Safety Network.
    Cumming M; Osinski A; O'Hearn L; Waksmonski P; Herman M; Gordon D; Griffiths E; Knox K; McHale E; Quillen K; Rios J; Pisciotto P; Uhl L; DeMaria A; Andrzejewski C
    Transfusion; 2017 Feb; 57(2):478-483. PubMed ID: 27774608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How is national recipient hemovigilance conducted in the United States?
    Chung KW; Harvey A; Basavaraju SV; Kuehnert MJ
    Transfusion; 2015 Apr; 55(4):703-7. PubMed ID: 25565577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfusion-related errors and associated adverse reactions and blood product wastage as reported to the National Healthcare Safety Network Hemovigilance Module, 2014-2022.
    Chavez Ortiz JL; Griffin I; Kazakova SV; Stewart PB; Kracalik I; Basavaraju SV
    Transfusion; 2024 Apr; 64(4):627-637. PubMed ID: 38476028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012.
    Harvey AR; Basavaraju SV; Chung KW; Kuehnert MJ
    Transfusion; 2015 Apr; 55(4):709-18. PubMed ID: 25371300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the National Healthcare Safety Network Hemovigilance Module for transfusion-related adverse reactions in the United States.
    Edens C; Haass KA; Cumming M; Osinski A; O'Hearn L; Passanisi K; Eaton L; Visintainer P; Savinkina A; Kuehnert MJ; Basavaraju SV; Andrzejewski C
    Transfusion; 2019 Feb; 59(2):524-533. PubMed ID: 30427540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of Transfusion-Related Adverse Reactions Among Apheresis Platelets, Whole Blood-Derived Platelets, and Platelets Subjected to Pathogen Reduction Technology as Reported to the National Healthcare Safety Network Hemovigilance Module.
    Mowla SJ; Kracalik IT; Sapiano MRP; O'Hearn L; Andrzejewski C; Basavaraju SV
    Transfus Med Rev; 2021 Apr; 35(2):78-84. PubMed ID: 33934903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusion-related adverse reactions: Data from the National Healthcare Safety Network Hemovigilance Module - United States, 2013-2018.
    Kracalik I; Mowla S; Basavaraju SV; Sapiano MRP
    Transfusion; 2021 May; 61(5):1424-1434. PubMed ID: 33880771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transfusion-Transmitted Infections Reported to the National Healthcare Safety Network Hemovigilance Module.
    Haass KA; Sapiano MRP; Savinkina A; Kuehnert MJ; Basavaraju SV
    Transfus Med Rev; 2019 Apr; 33(2):84-91. PubMed ID: 30930009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the quality of hemovigilance process using the first two steps of Six Sigma model: a cross-sectional study.
    Molaahmadi-Hassanabadi F; Mehrolhassani MH; Rahimisadegh R
    BMC Health Serv Res; 2023 Oct; 23(1):1169. PubMed ID: 37891622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion reaction reporting in the era of hemovigilance: where form meets function.
    Dunbar NM; Walsh SJ; Maynard KJ; Szczepiorkowski ZM
    Transfusion; 2011 Dec; 51(12):2583-7. PubMed ID: 21745209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [International databases: usefulness and limitations in hemovigilance].
    Wiersum-Osselton JC
    Transfus Clin Biol; 2010 Dec; 17(5-6):306-9. PubMed ID: 21055991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfusion-associated adverse events incidence and severity after the implementation of an active hemovigilance program with 24 h follow-up. A prospective cohort study.
    Bueno JL; Bocanegra AB; Sánchez I; Mateos JM; Puyuelo A; García Erce JA; Villanueva H; Reaño MM; Núñez L; Losa A; Arias A; Aguilar M; Richart LA; Martínez F; Salgado R; Royuela A; Cruz-Bermúdez JL; Fernández R; Forés R; Fornet I; Ojeda E; Cabrera R; Duarte RF
    Transfusion; 2023 Oct; 63(10):1859-1871. PubMed ID: 37711059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the early coronavirus disease 2019 pandemic on blood utilization in the United States: A time-series analysis of data reported to the National Healthcare Safety Network Hemovigilance Module.
    Kracalik I; Mowla S; Katz L; Cumming M; Sapiano MRP; Basavaraju SV
    Transfusion; 2021 Sep; 61 Suppl 2(Suppl 2):S36-S43. PubMed ID: 33990963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998.
    Andreu G; Morel P; Forestier F; Debeir J; Rebibo D; Janvier G; Hervé P
    Transfusion; 2002 Oct; 42(10):1356-64. PubMed ID: 12423521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thirty years of hemovigilance - Achievements and future perspectives.
    Vuk T; Politis C; Laspina S; Lozano M; Haddad A; de Angelis V; Garraud O;
    Transfus Clin Biol; 2023 Feb; 30(1):166-172. PubMed ID: 36216308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7-day storage.
    Pitman JP; Payrat JM; Park MS; Liu K; Corash L; Benjamin RJ
    Transfusion; 2023 Apr; 63(4):711-723. PubMed ID: 36802055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Implementation of hemovigilance in Sub-Saharan Africa].
    Dahourou H; Tapko JB; Nébié Y; Kiénou K; Sanou M; Diallo M; Barro L; Murphy E; Lefrère JJ
    Transfus Clin Biol; 2012 Feb; 19(1):39-45. PubMed ID: 22296906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model.
    Corash L; Benjamin RJ
    Transfusion; 2016 Mar; 56 Suppl 1():S29-38. PubMed ID: 27001358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events of red blood cell transfusions in patients with sickle cell disease.
    Rollins MR; Chou ST
    Transfus Apher Sci; 2022 Oct; 61(5):103557. PubMed ID: 36064527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.